<DOC>
	<DOC>NCT00148616</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of memantine as add-on treatment for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia. Primary outcome parameter are changes in negative symptoms between baseline and 6 months</brief_summary>
	<brief_title>Memantine for the Treatment of Negative Symptomatology</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Diagnosis of schizophrenia (DSMIV) Age 18 to 40 Stable negative syndrome (PANSS negative score &gt; 20) At least one previous schizophrenic episode Informed consent Subjects must be considered by the investigator to be compliant with investigations and appointments Subjects must have an educational level and a degree of understanding such that they can meaningfully communicate with the investigator Axis I disorder other than schizophrenia within 12 months, e.g. schizoaffective disorder Severe positive symptomatology (PANNS positive score &gt; PANNS negative score) Dependency on alcohol or addictive drugs within 6 months of the baseline evaluation Contraindication of risperidone Significant neurological, cardiovascular, hepatic, renal, metabolic, or other medical diseases or any clinically relevant abnormalities in laboratory tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Memantine</keyword>
	<keyword>Negative Syndrome</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognitive impairment</keyword>
</DOC>